Author: ["Sunil K Ahuja","Hemant Kulkarni","Gabriel Catano","Brian K Agan","Jose F Camargo","Weijing He","Robert J O'Connell","Vincent C Marconi","Judith Delmar","Joseph Eron","Robert A Clark","Simon Frost","Jeffrey Martin","Seema S Ahuja","Steven G Deeks","Susan Little","Douglas Richman","Frederick M Hecht","Matthew J Dolan"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
The basis for the extensive variability seen in the reconstitution of CD4+ T cell counts in HIV-infected individuals receiving highly active antiretroviral therapy (HAART) is not fully known. Here, we show that variations in CCL3L1 gene dose and CCR5 genotype, but not major histocompatibility complex HLA alleles, influence immune reconstitution, especially when HAART is initiated at <350 CD4+ T cells/mm3. The CCL3L1-CCR5 genotypes favoring CD4+ T cell recovery are similar to those that blunted CD4+ T cell depletion during the time before HAART became available (pre-HAART era), suggesting that a common CCL3L1-CCR5 genetic pathway regulates the balance between pathogenic and reparative processes from early in the disease course. Hence, CCL3L1-CCR5 variations influence HIV pathogenesis even in the presence of HAART and, therefore, may prospectively identify subjects in whom earlier initiation of therapy is more likely to mitigate immunologic failure despite viral suppression by HAART. Furthermore, as reconstitution of CD4+ cells during HAART is more sensitive to CCL3L1 dose than to CCR5 genotypes, CCL3L1 analogs might be efficacious in supporting immunological reconstitution.Cite this article
Ahuja, S., Kulkarni, H., Catano, G. et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals. Nat Med 14, 413–420 (2008). https://doi.org/10.1038/nm1741 